
Description
Cultrex®Human Vitronectin,Pathclear®ispurifiedfromhumanplasmaandisPathclear®certifiedtobefreeofcommonpathogens.Vitronectinisanextracellular,soluble,disulfide-linkeddimer,composedofa75kDaanda65kDapeptidechainwithatotalmolecularweightof140kDa.VitronectinisamajorplasmaglycoproteinthatpromotescellularadhesionandspreADIng.Italsoinhibitsthemembranedamagingeffectoftheterminalcytolyticcomplementpathwayandbindstoseveralserpinserineproteaseinhibitors.Vitronectin,alongwithcollagenIV,fibronectin,andlaminincansupportrobust,longtermproliferationofundifferentiatedhumanembryonicstemcells.Vitronectincanbeusedforcoatingtissueculturesurfacestopromotecelladhesion,proliferationanddifferentiation,orasanadditiveforserum-freemedia.Vitronectinispurifiedfromhumanplasmaandis0.2μmsterilefiltered.
Cultrex®HumanVitronectin,Pathclear®isapurifiedplasmaextracellularmatrix proteinthathasbeendeveloped,producedandqualifiedspecifically forcellculturestudieswherethepresenceofpathogensmaycauseconcern.
Qualitycontrolspecifications:
- PathClear®–testednegativeforeighthumanpathogenicvirusesincludingHepatitisA,BandC,HIV1and2,Hantaan,Seoul,andSinNombrebyPCR.
- Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPsterilitytestingguidelines.
- Endotoxinconcentration≤20EU/mlbyLimulusAmoebocyteLysate(LAL)assay.
- Proteinconcentrationof1mg/ml.
- NomycoplasmacontaminationdetectedbyPCR.
- Providedin10mMSodiumPhosphate,pH7.7,8MUrea,5mMEDTA,500mMNaCl.
- Purity ≥90%(SDS-PAGE).
- BIOLOGicalactivitydeterminedforeachlot:
- CellAttachment:TestedfortheABIlitytopromotecellattachmentandspreadingofHT1080humanfibrosarcomacells.
SafetyStatement:
AlthoughCultrex®HumanVitronectin,PathClear®hasbeentestedforthevirusesaboveitcontainshumansourcematerialandthereforeshouldbetreatedaspotentiallyinfectiousandhandledattheBiologicalSafetyLevel2tominimizeexposure.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
NaturalProteinStopsDeadlyHumanBrainCancerInMice
ScientistsfromJohnsHopkinsandfromtheUniversityofMilanhaveeffectivelyproventhattheycaninhibitlethalhumanbraincancersinmiceusingaproteinthatselectivelyinducespositivechangesintheactivityofcellsthatbehavelikecancerstemcells.ThereportispublishedinNature.
Themostcommontypeofbraincancer-glioblastoma-ismarkedbythepresenceofthesestem-cell-likebraincells,which,insteadoftriggeringthereplacementofdamagedcells,formcancertissue.Stemcells,unlikeallothercellsinthebody,arecapableofformingalmostanykindofcellwhentheright"signals"triggertheirdevelopment.
Fortheirtreatmentexperiment,theresearchersreliedonaclassofproteins,bonemorphogenicproteins,thatcauseneuralstem-cell-likeclusterstolosetheirstemcellproperties,whichinturnstopstheirABIlitytodivide.
Firsttheypretreatedhumanglioblastomacellswithbonemorphogenicprotein4(BMP4),theninjectedthesetreatedcellsintomousebrains.Inmiceinjectedwithcellsthatwerenotpretreated,large,invasivecancersgrew.InthemicewithBMP4-treatedcells,nocancersgrewatall.Threetofourmonthsafterinjection,allmicethatgotuntreatedcellsdied,andnearlyallmicewithBMP4-treatedcellswerealive.
Next,thescientistsdeliveredslow-releaseBMP4-containing"beads"directlyintomousebrainswithimplantedglioblastomacells.Micethatgotemptybeadsdevelopedlargemalignanttumorsanddied.MicewithBMP4beadssurvivedmuchlonger,and80percentsurvivedfourmonthsaftercancercellimplants.
"OurideaistotreatpatientswithBMP4orsomethinglikeitrightaftersurgerytoremoveglioblastomainhopesofpreventingtheregrowthofthecancerandimprovingsurvivaltime,"saysAlessandroOlivi,M.D.,directoroftheDivisionofNeurosurgicalOncologyatHopkinsandacontributortothestudy.
OlivisaysclinicalstudiesusingBMP4couldbeginwithinayearand,ifsuccessful,drugtherapiescouldbeavailabletothepublicwithinthreetofouryears.
"ThiswasproofoftheideathatBMPscouldstopglioblastomabydepletingthestem-cell-likepopulationthatfeedsit,"saysHenryBrem,M.D.,chairmanoftheDepartmentofNeurosurgeryatHopkinsandacollaboratorinthestudy."Thisopensexcitingdoorstofutureresearchintotreatmentsandtherapiesforsuchadevastatingdisease."
算上其他生物24种
大概是记不太清了

